Company: Takeda Pharmaceutical Co. Ltd.
Job title: Principal Scientist
Targeting STING to CCR2+ Cells Via an Immune Stimulating Antibody Conjugate 12:00 pm
The murine surrogate ISAC, mTAK-500, was designed to selectively deliver the STING agonist, TAK-676, to CCR2+ cells mTAK-500 enabled the characterization of the exposure, potency, mechanism, and anti-tumor activity of targeting STING to CCR2+ cells CCR2-mediated delivery of TAK-676 triggered dose-dependent activation of the STING signaling pathway, as well as robust activation of innate and…Read more
day: Scientific Program Day One